CRISPR基因组疗法市场－全球产业规模、份额、趋势、机会及预测（依疾病类型、治疗类型、给药方式、最终用户、标靶基因修饰、地区和竞争格局划分，2021-2031年）

全球 CRISPR 基因组疗法市场预计将从 2025 年的 36.9 亿美元成长到 2031 年的 141.8 亿美元，复合年增长率达到 25.15%。

该市场指的是利用丛集规律间隔短回文重复序列（CRISPR）技术，透过治疗性介入对遗传物质进行精确编辑，以治疗癌症和严重先天性疾病。全球遗传疾病盛行率的不断上升以及关键监管核准批准基因编辑的临床疗效，是推动市场成长的主要因素，同时强大的研发管线也为其提供了有力支撑。根据美国基因与细胞治疗学会（ASCT）统计，截至2024年第一季，全球有超过4000种基因、细胞和RNA疗法正在研发中，凸显了推动市场加速发展的庞大规模。

然而，由于生产和治疗成本高昂，这些疗法的应用仍存在许多障碍，尤其是在医保报销方面。这些经济障碍常常会延迟药物上市，并限制已通过核准治疗方法的商业性扩充性，尤其是在医疗预算有限的地区。因此，建立永续的定价模式仍然是一项重大挑战，可能会阻碍这些疗法的广泛治疗方法。

市场驱动因素

First-in-Class基因编辑治疗方法的商业性检验与上市是市场扩张的重要催化剂，标誌着CRISPR技术正从实验科学走向实际治疗应用。 Exagamgrogen Autotemcel（Casgevy）近期获得监管部门核准并投入商业性应用，为临床疗效树立了重要先例，有助于更广泛的应用和基础设施建设。製药公司正积极建立一个专门的网络来管理这些复杂的治疗方法。例如，Vertex Pharmaceuticals在其2024年11月发布的第三季财报中指出，截至10月中旬，该公司已在全球范围内运作了45家经认证的治疗中心，以支持其基于CRISPR治疗方法的商业性化应用，这表明该行业致力于克服物流方面的挑战。

另一个推动因素是创业投资和政府对基因组学研究的资助激增，这对于维持临床开发和生产创新的高成本至关重要。儘管面临更广泛的经济逆风，该领域仍持续吸引大量资金，使生技公司能够推进其研发管线并改善递送机制。根据再生医学联盟在2024年10月举行的梅萨细胞与基因会议上的报告，2024年上半年全球对细胞和基因治疗领域的投资达109亿美元。这笔资金的涌入为新兴企业公司和成熟公司都提供了支持。例如，CRISPR Therapeutics公司在其2024年11月发布的「2024年第三季财报」中表示，公司拥有约19亿美元的现金和证券，财务状况稳健，确保了其正在进行的临床项目的持续资源供应。

市场挑战

全球CRISPR基因组疗法市场面临许多挑战，主要原因在于其生产和应用高成本。这类治疗性介入通常需要复杂的个人化生产流程，对患者细胞进行改造后再重新导入体内，这需要专门的设施和严格的品管。这种复杂的供应链必然会增加营运成本，迫使製药公司提高价格以弥补巨额研发投入。这导致保险公司和预算有限的国家医疗体系对其产生抵触情绪。

这些高昂的定价结构造成了巨大的报销壁垒，限制了病患的就医途径，并延缓了商业性推广。支付方经常仔细审查这些资本密集、单剂量疗法的价值，导致漫长的谈判期和延迟报销。据再生医学联盟称，首个核准的基于 CRISPR 的治疗方法在 2024 年的定价为每位患者 220 万美元。如此沉重的经济负担阻碍了这些根治性治疗方法的广泛应用，尤其是在医疗资金有限的地区，直接抑制了整体市场扩张和收入潜力。

市场趋势

向精准的先导基因编辑和碱基编辑的转变代表着市场的一次根本性变革。它超越了第一代Cas9酶产生的双链断裂，朝着更安全地修正点突变的方向发展。这一趋势的特点是，业界对能够解决复杂基因异常且无脱靶效应或染色体易位风险的技术信心日益增强，製药公司也正透过策略性投资不断验证这些平台。在2024年9月发布的「策略重点研发管线公告」中，Prime Medicine宣布已与百时美施贵宝公司合作开发体外T细胞疗法。该公司接受1.1亿美元的预付款，用于进一步开发这项新一代基因编辑技术。

同时，体内递送机制，特别是非病毒脂质奈米颗粒（LNP），正迅速发展，旨在规避体外细胞工程的物流流程。这些载体能够直接系统性地递送基因编辑装置，显着降低了目前自体疗法的生产负担和基础设施需求。该领域的临床进展表明，LNP包裹的CRISPR组件能够实现显着的治疗效果。根据Intellia Therapeutics公司2024年10月发布的报告《NTLA-2002公布II期研究的积极结果》，该公司的一项体内实验性治疗，单次50毫克剂量即可使平均每月癫痫发作率较安慰剂组降低81%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球CRISPR基因组疗法市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依疾病类型（遗传性疾病、癌症、感染疾病、神经系统疾病、心血管疾病、血液疾病、代谢性疾病、其他）
  • 依治疗方法（基因编辑、基因治疗、细胞治疗、免疫疗法）
  • 依给药途径（体内给药、体外给药）
  • 依最终用户（医院/诊所、研究机构、生技/製药公司）划分
  • 透过标靶基因修饰（单基因修饰、多基因修饰、全基因组修饰）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美CRISPR基因组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲 CRISPR 基因组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区CRISPR基因组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲 CRISPR 基因组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲CRISPR基因组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球CRISPR基因组疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Merck KGaA
• Takara Bio Inc
• Lonza Group AG
• Horizon Discovery Group Ltd
• Genscript Biotech Corp
• Synthego Corp
• Precision BioSciences Inc
• Mammoth Biosciences Inc
• Thermo Fisher Scientific Inc
• Intellia Therapeutics Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Crispr Genomic Cure Market is projected to expand from USD 3.69 Billion in 2025 to USD 14.18 Billion by 2031, achieving a Compound Annual Growth Rate (CAGR) of 25.15%. This market involves therapeutic interventions utilizing Clustered Regularly Interspaced Short Palindromic Repeats technology to precisely edit genetic material for the treatment of oncology indications and severe congenital disorders. The market's growth is driven by the increasing global prevalence of genetic diseases and significant regulatory approvals that have validated the clinical efficacy of gene editing, further supported by a robust industrial pipeline. According to the American Society of Gene & Cell Therapy, over 4,000 gene, cell, and RNA therapies were in development globally during the first quarter of 2024, highlighting the immense scale of activity propelling market acceleration.

However, the sector encounters a major obstacle due to the exorbitant costs linked to manufacturing and patient administration, which create substantial reimbursement hurdles. These financial barriers frequently delay market access and restrict the commercial scalability of approved therapies, especially in regions with limited healthcare budgets. Consequently, establishing sustainable pricing models remains the primary challenge that could hinder the widespread adoption of these curative treatments.

Market Driver

The commercial validation and launch of first-in-class gene editing treatments act as a primary catalyst for market expansion, signaling the transition of CRISPR technology from experimental science to viable therapeutic reality. The recent regulatory approvals and commercial rollout of exagamglogene autotemcel (Casgevy) have set a critical precedent for clinical efficacy, fostering wider adoption and infrastructure development. Pharmaceutical companies are aggressively building specialized networks to administer these complex therapies; for instance, Vertex Pharmaceuticals reported in its 'Third Quarter 2024 Financial Results' in November 2024 that it had activated 45 authorized treatment centers globally by mid-October to support the commercial administration of its CRISPR-based therapy, demonstrating the industry's commitment to overcoming logistical challenges.

A parallel driver is the surge in venture capital and government funding for genomic research, which is essential for sustaining the high costs of clinical development and manufacturing innovation. Despite broader economic headwinds, the sector continues to attract significant capital, enabling biotechnology firms to advance their pipelines and refine delivery mechanisms. According to the Alliance for Regenerative Medicine's October 2024 presentation at the 'Cell & Gene Meeting on the Mesa', global investment in the cell and gene therapy sector reached $10.9 billion in the first half of 2024. This financial influx supports both startups and established players; for example, CRISPR Therapeutics noted in its 'Third Quarter 2024 Financial Results' in November 2024 that it maintained a robust balance sheet with approximately $1.9 billion in cash and securities, ensuring sustained resources for its ongoing clinical programs.

Market Challenge

The Global CRISPR Genomic Cure Market faces a significant impediment due to the high costs associated with manufacturing and patient administration. These therapeutic interventions typically necessitate complex, individualized production processes where patient cells are modified and reintroduced, requiring specialized facilities and rigorous quality control. This intricate supply chain inherently raises operational expenditures, compelling pharmaceutical developers to set high market prices to recover their substantial research and development outlays, which creates friction with insurance providers and national health systems operating under finite budgets.

These elevated pricing structures result in severe reimbursement hurdles that restrict patient access and slow commercial adoption. Payers frequently scrutinize the value of such capital-intensive one-time treatments, leading to prolonged negotiation periods and coverage delays. According to the Alliance for Regenerative Medicine, the list price for the first approved CRISPR-based therapy was established at $2.2 million per patient in 2024. This distinct financial burden limits the widespread scalability of these curative options, particularly in regions with constrained healthcare funding, thereby directly hampering the overall expansion and revenue potential of the market.

Market Trends

The transition to high-precision prime and base editing represents a fundamental shift in the market, moving beyond the double-strand breaks induced by first-generation Cas9 enzymes to potentially safer corrections of point mutations. This trend is characterized by growing industrial confidence in these technologies to address complex genetic errors without the risks of off-target effects or chromosomal translocations, with pharmaceutical entities increasingly validating these platforms through strategic investments. According to Prime Medicine, in its September 2024 'Prime Medicine Unveils Strategically Focused Pipeline' announcement, the company entered a collaboration with Bristol Myers Squibb to develop ex vivo T-cell therapies, receiving an upfront consideration of $110 million to advance these next-generation editing capabilities.

Simultaneously, the market is experiencing rapid advancement in in vivo delivery mechanisms, particularly non-viral lipid nanoparticles (LNPs), which aim to circumvent the logistical complexities of ex vivo cell engineering. By enabling the direct systemic administration of gene editors, these vectors significantly reduce the manufacturing burden and infrastructure requirements associated with current autologous therapies. Clinical progress in this domain is demonstrating the capability of LNP-encapsulated CRISPR components to achieve potent therapeutic outcomes; according to Intellia Therapeutics' October 2024 report 'Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002', a single 50 mg dose of their in vivo investigational therapy resulted in a mean monthly attack rate reduction of 81% compared to placebo.

Key Market Players

• Merck KGaA
• Takara Bio Inc
• Lonza Group AG
• Horizon Discovery Group Ltd
• Genscript Biotech Corp
• Synthego Corp
• Precision BioSciences Inc
• Mammoth Biosciences Inc
• Thermo Fisher Scientific Inc
• Intellia Therapeutics Inc

Report Scope

In this report, the Global Crispr Genomic Cure Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Crispr Genomic Cure Market, By Disease Type

• Genetic Disorders
• Cancer
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disorders
• Blood Disorders
• Metabolic Disorders
• Others

Crispr Genomic Cure Market, By Therapy Type

• Gene Editing
• Gene Therapy
• Cell Therapy
• Immunotherapy

Crispr Genomic Cure Market, By Delivery Method

• In vivo
• Ex vivo

Crispr Genomic Cure Market, By End User

• Hospitals & Clinics
• Research Institutes
• Biotechnology & Pharmaceutical Companies

Crispr Genomic Cure Market, By Targeted Genetic Modification

• Single Gene Modification
• Multiple Gene Modification
• Genome-wide Modification

Crispr Genomic Cure Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Crispr Genomic Cure Market.

Available Customizations:

Global Crispr Genomic Cure Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Crispr Genomic Cure Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
  • 5.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
  • 5.2.3. By Delivery Method (In vivo, Ex vivo)
  • 5.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
  • 5.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Crispr Genomic Cure Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy Type
  • 6.2.3. By Delivery Method
  • 6.2.4. By End User
  • 6.2.5. By Targeted Genetic Modification
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Crispr Genomic Cure Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy Type
      • 6.3.1.2.3. By Delivery Method
      • 6.3.1.2.4. By End User
      • 6.3.1.2.5. By Targeted Genetic Modification
  • 6.3.2. Canada Crispr Genomic Cure Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy Type
      • 6.3.2.2.3. By Delivery Method
      • 6.3.2.2.4. By End User
      • 6.3.2.2.5. By Targeted Genetic Modification
  • 6.3.3. Mexico Crispr Genomic Cure Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy Type
      • 6.3.3.2.3. By Delivery Method
      • 6.3.3.2.4. By End User
      • 6.3.3.2.5. By Targeted Genetic Modification

7. Europe Crispr Genomic Cure Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy Type
  • 7.2.3. By Delivery Method
  • 7.2.4. By End User
  • 7.2.5. By Targeted Genetic Modification
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Crispr Genomic Cure Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy Type
      • 7.3.1.2.3. By Delivery Method
      • 7.3.1.2.4. By End User
      • 7.3.1.2.5. By Targeted Genetic Modification
  • 7.3.2. France Crispr Genomic Cure Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy Type
      • 7.3.2.2.3. By Delivery Method
      • 7.3.2.2.4. By End User
      • 7.3.2.2.5. By Targeted Genetic Modification
  • 7.3.3. United Kingdom Crispr Genomic Cure Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy Type
      • 7.3.3.2.3. By Delivery Method
      • 7.3.3.2.4. By End User
      • 7.3.3.2.5. By Targeted Genetic Modification
  • 7.3.4. Italy Crispr Genomic Cure Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy Type
      • 7.3.4.2.3. By Delivery Method
      • 7.3.4.2.4. By End User
      • 7.3.4.2.5. By Targeted Genetic Modification
  • 7.3.5. Spain Crispr Genomic Cure Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy Type
      • 7.3.5.2.3. By Delivery Method
      • 7.3.5.2.4. By End User
      • 7.3.5.2.5. By Targeted Genetic Modification

8. Asia Pacific Crispr Genomic Cure Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy Type
  • 8.2.3. By Delivery Method
  • 8.2.4. By End User
  • 8.2.5. By Targeted Genetic Modification
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Crispr Genomic Cure Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy Type
      • 8.3.1.2.3. By Delivery Method
      • 8.3.1.2.4. By End User
      • 8.3.1.2.5. By Targeted Genetic Modification
  • 8.3.2. India Crispr Genomic Cure Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy Type
      • 8.3.2.2.3. By Delivery Method
      • 8.3.2.2.4. By End User
      • 8.3.2.2.5. By Targeted Genetic Modification
  • 8.3.3. Japan Crispr Genomic Cure Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy Type
      • 8.3.3.2.3. By Delivery Method
      • 8.3.3.2.4. By End User
      • 8.3.3.2.5. By Targeted Genetic Modification
  • 8.3.4. South Korea Crispr Genomic Cure Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy Type
      • 8.3.4.2.3. By Delivery Method
      • 8.3.4.2.4. By End User
      • 8.3.4.2.5. By Targeted Genetic Modification
  • 8.3.5. Australia Crispr Genomic Cure Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy Type
      • 8.3.5.2.3. By Delivery Method
      • 8.3.5.2.4. By End User
      • 8.3.5.2.5. By Targeted Genetic Modification

9. Middle East & Africa Crispr Genomic Cure Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy Type
  • 9.2.3. By Delivery Method
  • 9.2.4. By End User
  • 9.2.5. By Targeted Genetic Modification
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Crispr Genomic Cure Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy Type
      • 9.3.1.2.3. By Delivery Method
      • 9.3.1.2.4. By End User
      • 9.3.1.2.5. By Targeted Genetic Modification
  • 9.3.2. UAE Crispr Genomic Cure Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy Type
      • 9.3.2.2.3. By Delivery Method
      • 9.3.2.2.4. By End User
      • 9.3.2.2.5. By Targeted Genetic Modification
  • 9.3.3. South Africa Crispr Genomic Cure Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy Type
      • 9.3.3.2.3. By Delivery Method
      • 9.3.3.2.4. By End User
      • 9.3.3.2.5. By Targeted Genetic Modification

10. South America Crispr Genomic Cure Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy Type
  • 10.2.3. By Delivery Method
  • 10.2.4. By End User
  • 10.2.5. By Targeted Genetic Modification
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Crispr Genomic Cure Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy Type
      • 10.3.1.2.3. By Delivery Method
      • 10.3.1.2.4. By End User
      • 10.3.1.2.5. By Targeted Genetic Modification
  • 10.3.2. Colombia Crispr Genomic Cure Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy Type
      • 10.3.2.2.3. By Delivery Method
      • 10.3.2.2.4. By End User
      • 10.3.2.2.5. By Targeted Genetic Modification
  • 10.3.3. Argentina Crispr Genomic Cure Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy Type
      • 10.3.3.2.3. By Delivery Method
      • 10.3.3.2.4. By End User
      • 10.3.3.2.5. By Targeted Genetic Modification

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Crispr Genomic Cure Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Takara Bio Inc
• 15.3. Lonza Group AG
• 15.4. Horizon Discovery Group Ltd
• 15.5. Genscript Biotech Corp
• 15.6. Synthego Corp
• 15.7. Precision BioSciences Inc
• 15.8. Mammoth Biosciences Inc
• 15.9. Thermo Fisher Scientific Inc
• 15.10. Intellia Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer